NDC 69339-160-01 - Megestrol Acetate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 69339-160
- Requested NDC
- 69339-160-01
- Package NDCs from labels
- 69339-160-01, 69339-160-16, 69339-160-17, 69339-160-18, 69339-160-19
- Manufacturer
- Natco Pharma USA LLC | Strides Pharma, Inc
- Effective date
- 2026-01-15
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Megestrol Acetate - Natco Pharma USA LLC | Strides Pharma, Inc | Natco Pharma USA LLC | Strides Pharma, Inc | 2026-01-15 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69339-160-01 | Megestrol Acetate | 10 mL in 1 CUP, UNIT-DOSE | SUSPENSION | 10 | 2 | |
| 69339-160-16 | Megestrol Acetate | 3 in 1 CASE | SUSPENSION | 3 | 2 | |
| 69339-160-16 | Megestrol Acetate | 10 in 1 TRAY | SUSPENSION | 10 | 2 | |
| 69339-160-17 | Megestrol Acetate | 4 in 1 CASE | SUSPENSION | 4 | 2 | |
| 69339-160-17 | Megestrol Acetate | 10 in 1 TRAY | SUSPENSION | 10 | 2 | |
| 69339-160-18 | Megestrol Acetate | 10 in 1 TRAY | SUSPENSION | 10 | 2 | |
| 69339-160-18 | Megestrol Acetate | 5 in 1 CASE | SUSPENSION | 5 | 2 | |
| 69339-160-19 | Megestrol Acetate | 10 in 1 CASE | SUSPENSION | 10 | 2 | |
| 69339-160-19 | Megestrol Acetate | 10 in 1 TRAY | SUSPENSION | 10 | 2 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69339-160-01 | ML - Milliliter | 69339-160 | 67edb6da-5e2c-4fcc-8a4a-3b098aaff6eb | 1 | 2023-09-05 |
| 69339-160-16 | ML - Milliliter | 69339-160 | 27f6e6c7-08d3-442e-b959-3a663f185453 | 1 | 2023-09-05 |
| 69339-160-17 | ML - Milliliter | 69339-160 | 31b3dcc7-2913-4c24-b3a6-640158ec6c37 | 1 | 2023-09-05 |
| 69339-160-18 | ML - Milliliter | 69339-160 | 59fcc138-63c5-45d5-b946-93f453f55056 | 1 | 2023-09-05 |
| 69339-160-19 | ML - Milliliter | 69339-160 | da7e552a-6eec-4c7f-993b-b3d609d66d99 | 1 | 2023-09-05 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Docusate Sodium | DOCUSATE SODIUM | AvPAK | f31a4349-7826-45c0-9388-6b938d167b7a | 2025-01-09 | Warnings | F05Q2T2JA0 |
| Docusate sodium | DOCUSATE SODIUM | APNAR PHARMA LP | 05b0732b-012f-78ee-e063-6294a90a839a | 2025-01-09 | Warnings | F05Q2T2JA0 |
| A-5 | SUCROSE | DNA Labs, Inc. | 8e63f697-26c1-4518-acd3-5ea72cfa27f7 | 2025-01-09 | Warnings | C151H8M554 |
| Hemorrhoidal Cream with Aloe | GLYCEROL, PHENYLEPHINE, PRAMOXINE, PETROLATUM | Chain Drug Marketing Association | 2b33c710-ac17-20f9-e063-6294a90ad29c | 2025-01-08 | Warnings | PDC6A3C0OX |
| ANTIBACTERIAL DREAMY FLORALS | GLYCERIN | Quimicas Handal de Centroamerica SA de CV | 09f73bec-516d-90f0-e063-6394a90aecab | 2025-01-08 | Warnings | PDC6A3C0OX |
| DOCUSATE SODIUM | DOCUSATE SODIUM | Safecor Health, LLC | efe4bf81-fb99-4755-aa23-4f8df5973be8 | 2025-01-08 | Warnings | F05Q2T2JA0 |
| Senexon-S | DOCUSATE SODIUM 50MG AND SENNOSIDES 8.6MG | NCS HealthCare of KY, LLC dba Vangard Labs | c049ef78-cc16-4209-b553-60cead5c9a80 | 2025-01-03 | Warnings | F05Q2T2JA0 |
| Prevention Oncology Mouth Rinse | GLYCERIN | Prevention Health Sciences, Inc. | 1ec9ed1c-bcb6-3a0a-e054-00144ff8d46c | 2025-01-01 | Warnings | PDC6A3C0OX |
| CLENZIDERM THERAPEUTIC MOISTURIZER | GLYCERIN | Obagi Cosmeceuticals LLC | d60e22e3-831e-4787-a82c-e7763c287553 | 2025-01-01 | Warnings | PDC6A3C0OX |
| Laxative Docusate Sodium with Senna | DOCUSATE SODIUM AND SENNOSIDES | TOPCO ASSOCIATES LLC | cf9075d8-e20e-419a-b996-9b12f49f05f2 | 2025-01-01 | Warnings | F05Q2T2JA0 |
| Vegetable Laxative and Stool Softner | DOCUSATE SODIUM AND SENNOSIDES | TOPCO ASSOCIATES LLC | e84d693d-0041-4c11-8f6a-b5c332f79af9 | 2025-01-01 | Warnings | F05Q2T2JA0 |
| Laxacin | DOCUSATE SODIUM AND SENNOSIDES | Advanced Rx Pharmacy of Tennessee, LLC | fe7d4d75-0f8a-1e7d-e053-6394a90afb4d | 2024-12-31 | Warnings | F05Q2T2JA0 |
| DOCUSATE SODIUM | DOCUSATE SODIUM | A-S Medication Solutions | 946abcdb-96bd-43e6-992a-bb97679c00f0 | 2024-12-30 | Warnings | F05Q2T2JA0 |
| Gut Brain Spectrum | ABROTANUM (ARTEMISIA ABROTANUM), AETHUSA CYNAPIUM, BAPTISIA TINCTORIA, CICUTA VIROSA, CUPRUM METALLICUM, MEZEREUM, BUFO RANA, LAC MATERNA HUMANUM, SACCHARUM OFFICINALE, SEROTONIN (HYDROCHLORIDE), ALUMINA, CALCAREA PHOSPHORICA, CANDIDA ALBICANS, CARCINOSIN, LAC CANINUM, MERCURIUS SOLUBILIS, NATRUM MURIATICUM, PROPIONIC ACID, SULPHUR, THUJA OCCIDENTALIS, FORMALINUM, MORBILLINUM | Energique, Inc. | adfee6ce-05b0-4955-bf5f-9612b8db4c78 | 2024-12-26 | Warnings | C151H8M554 |
| Tucks Triple Relief Hemorrhoidal | WHITE PETROLATUM, GLYCERIN, PRAMOXINE HYDROCHLORIDE, AND PHENYLEPHRINE HYDROCHLORIDE | Blistex Inc. | bf892e90-2d9b-4fa0-8ee4-8a2736be6c30 | 2024-12-24 | Warnings | PDC6A3C0OX |
| Pedia-Lax | GLYCERIN | C.B. Fleet Company, Inc. | 4e15f6ca-a40c-485f-be3f-07c2ed7cb498 | 2024-12-23 | Warnings | PDC6A3C0OX |
| OASIS Tears Preservative-Free Lubricant Eye | GLYCERIN | OASIS Medical, Inc. | d9d71b1d-82a6-42e7-9ef2-2d041daef936 | 2024-12-23 | Warnings | PDC6A3C0OX |
| GeriCare Docusate Sodium Liquid | DOCUSATE SODIUM | GERI-CARE PHARMACEUTICALS, CORP | e50558e1-f0c8-4b03-9109-6a273b61730d | 2024-12-20 | Warnings | F05Q2T2JA0 |
| DCH Hemorrhoidal | GLYCERIN 14.4%, LIDOCAINE 5%, PETROLATUM 15%, PHENYLEPHRINE HCL 0.25% | Derma Care Research Labs, LLC | 0050701f-4393-3f01-e063-6394a90a4e0e | 2024-12-19 | Warnings | PDC6A3C0OX |
| Revivol Hemorrhoid and Fissure | GLYCERIN 14.4%, LIDOCAINE 5%, PETROLATUM 15%, PHENYLEPHRINE HCL 0.25% | Derma Care Research Labs, LLC | 0140cf68-b6a0-4378-e063-6394a90afee8 | 2024-12-19 | Warnings | PDC6A3C0OX |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.